receptors. The development of mechanism-based screens for nuclear receptor agonists and antagonists was the focus of his research when he moved back to Baylor College of Medicine as an Assistant Professor of Cell Biology. Given this interest in drug discovery, it was not a surprise that in 1991 he again returned to the private sector as Director and Head of Molecular Biology at Ligand Pharmaceuticals in San Diego. After three very exciting years in industry, he moved to Duke where his work has focused on the genetic and pharmacological dissection of the nuclear receptor signal transduction pathways. The insights from this work have led to the discovery and development of novel estrogen and androgen receptor modulators, some of which have advanced to the clinic and are being evaluated as treatments for a variety of endocrinopathies.
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